bioAffinity Technologies Stock Surged A Whopping 79% Today – Here’s An Important Update

Shares of bioAffinity Technologies (BIAF) soared 79% on Friday after the company released three additional case studies, including one in which the use of its CyPath Lung test led to the detection of lung cancer at an early, possibly curable stage.

The company also stated that two potentially risky invasive procedures were avoided for patients facing difficult healthcare choices by using the test.

CyPath Lung is a non-invasive test designed to enhance the early detection of lung cancer in patients at high risk for the disease. It uses advanced flow cytometry and artificial intelligence (AI) to identify cell populations in a patient’s sputum that indicate malignancy. In clinical studies, it was demonstrated that CyPath Lung had a sensitivity of 92%, specificity of 87%, and an accuracy of 88%.

On Stocktwits, retail sentiment around BIAF stock rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.

BioAffinity stated that the three new cases were provided by a Texas pulmonologist who has been using the test for over a year. While early-stage lung cancer was diagnosed in 68-year-old Samuel with the help of the test, David avoided an unnecessary biopsy after the test came out negative. Lisa, with a previous diagnosis of lung cancer, proceeded with radiation therapy after a positive CyPath Lung result without performing a biopsy, as she might not have been healthy enough for the procedure.

“We believe CyPath Lung can be a transformative tool in the lung cancer diagnostic pathway, especially when imaging results are inconclusive. A positive CyPath Lung result can lead to earlier diagnosis and treatment, and a negative result can spare patients from unnecessary invasive procedures,” Chief Medical Officer Gordon Downie said.

BIAF stock is down 78% this year and by 90% over the past 12 months. 

Read also: Pharmaceutical Tariffs ‘A Light At The End Of The Trump Tunnel’ For Big Pharma, Says Jefferies

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on